Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
30
LABFF Quote, Financials, Valuation and Earnings
Last price:
$65.86
Seasonality move
:
-7.81%
Day range:
$65.86 - $65.86
52-week range:
$65.86 - $90.61
Dividend yield:
1.66%
P/E ratio:
24.71x
P/S ratio:
4.20x
P/B ratio:
4.61x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$3.4B
Revenue:
$826.1M
EPS (TTM):
$2.67
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Laboratorios Farmaceúticos Rovi SA has -- downside to fair value with a price target of -- per share.
LABFF vs. S&P 500
-
Over the past 5 trading days, Laboratorios Farmaceúticos Rovi SA has underperformed the S&P 500 by -0.31% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Laboratorios Farmaceúticos Rovi SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Laboratorios Farmaceúticos Rovi SA revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Laboratorios Farmaceúticos Rovi SA reported revenues of $245.9M.
Earnings Growth
-
Laboratorios Farmaceúticos Rovi SA earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Laboratorios Farmaceúticos Rovi SA reported earnings per share of $1.33.
Enterprise value:
3.5B
EV / Invested capital:
3.90x
Price / LTM sales:
4.20x
EV / EBIT:
20.52x
EV / Revenue:
4.32x
PEG ratio (5yr expected):
3.93x
EV / Free cash flow:
29.40x
Price / Operating cash flow:
28.55x
Enterprise value / EBITDA:
17.19x
Gross Profit (TTM):
$481.4M
Return On Assets:
14.13%
Net Income Margin (TTM):
16.98%
Return On Equity:
20.71%
Return On Invested Capital:
17.18%
Operating Margin:
32.3%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $891.3M | $866.7M | $802.5M | $258.5M | $245.9M | |
| Gross Profit | $536.2M | $509.6M | $481.4M | $171.5M | $164M | |
| Operating Income | $266.1M | $230.9M | $169.1M | $98.9M | $79.4M | |
| EBITDA | $291.4M | $260.3M | $201.9M | $106.8M | $88.2M | |
| Diluted EPS | $3.90 | $3.47 | $2.67 | $1.50 | $1.33 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $552.2M | $532.6M | $600.4M | $618.1M | $657M | |
| Total Assets | $794M | $756.7M | $879.5M | $979.7M | $1.1B | |
| Current Liabilities | $184.8M | $253.1M | $233.7M | $247.2M | $217.9M | |
| Total Liabilities | $268.9M | $322.5M | $292.3M | $356.8M | $339.9M | |
| Total Equity | $525M | $434.3M | $587.2M | $623M | $743.5M | |
| Total Debt | $83.3M | $65.4M | $55.1M | $105.2M | $114.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $126.4M | $136.2M | $192.2M | $38.7M | $86.1M | |
| Cash From Investing | -$68.9M | -$65.8M | -$92.4M | -$17.1M | -$21.4M | |
| Cash From Financing | -$104.4M | -$112.3M | -$65.9M | -$50.9M | -$60.4M | |
| Free Cash Flow | $63.7M | $68.5M | $118M | $21.6M | $64.8M | |
LABFF
Sector
Market Cap
$3.4B
$28.5M
Price % of 52-Week High
72.69%
51.44%
Dividend Yield
1.66%
0%
Shareholder Yield
1.47%
-1.33%
1-Year Price Total Return
--
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
1.66%
Annualized payout:
$1.20
Payout ratio:
-41.68%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$65.86
200-day SMA
Sell
Level
$66.23
Bollinger Bands (100)
Sell
Level
65.86 - 65.86
Chaikin Money Flow
Buy
Level
938
20-day SMA
Sell
Level
$65.86
Relative Strength Index (RSI14)
Sell
Level
48.15
ADX Line
Sell
Level
3.69
Williams %R
Buy
Level
0
50-day SMA
Sell
Level
$65.86
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Sell
Level
-1.2K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.8223)
Buy
CA Score
(Annual)
Level (1.7357)
Buy
Beneish M-Score
(Annual)
Level (-2.7868)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-2.8864)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.
Stock Forecast FAQ
In the current month, LABFF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LABFF average analyst price target in the past 3 months is --.
-
Where Will Laboratorios Farmaceúticos Rovi SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Laboratorios Farmaceúticos Rovi SA share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Laboratorios Farmaceúticos Rovi SA?
Analysts are divided on their view about Laboratorios Farmaceúticos Rovi SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Laboratorios Farmaceúticos Rovi SA is a Sell and believe this share price will rise from its current level to --.
-
What Is Laboratorios Farmaceúticos Rovi SA's Price Target?
The price target for Laboratorios Farmaceúticos Rovi SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LABFF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Laboratorios Farmaceúticos Rovi SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of LABFF?
You can purchase shares of Laboratorios Farmaceúticos Rovi SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Laboratorios Farmaceúticos Rovi SA shares.
-
What Is The Laboratorios Farmaceúticos Rovi SA Share Price Today?
Laboratorios Farmaceúticos Rovi SA was last trading at $65.86 per share. This represents the most recent stock quote for Laboratorios Farmaceúticos Rovi SA. Yesterday, Laboratorios Farmaceúticos Rovi SA closed at $65.86 per share.
-
How To Buy Laboratorios Farmaceúticos Rovi SA Stock Online?
In order to purchase Laboratorios Farmaceúticos Rovi SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get LABFF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LABFF
Sector
P/E ratio
24.71x
23.75x
PEG ratio
3.93x
-0.01x
P/B ratio
4.61x
1.83x
Price / LTM sales
4.20x
1.60x
Growth Metrics
LABFF
Sector
Revenue growth
-4.84%
4.85%
Earnings growth
-11.54%
11.11%
Revenue (5-year growth)
14.12%
6.45%
Earnings forecast
--
-$0.20
Profitability
LABFF
Sector
Profitability FY 2024
$486.4M
$3.6M
Return on invested capital
17.18%
-30.98%
Return on assets
14.13%
-27.62%
Return on equity
20.71%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
5
Balance Sheet
LABFF
Sector
Total cash
$57.9M
$27.2M
Short term investments
$236.2K
$25.7M
Total assets
$861.6M
$79.7M
Long term debt
$114.3M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 48.08% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 5.53% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
